In this Phase III , multicenter , parallel-group , double-blind study , drug-naive patients with glycosylated hemoglobin ( HbA@c ) levels @ % to @ % ( @-@ mmol/mol ) were randomized ( by using an interactive voice response system ) to receive placebo ( n = @ ) , dapagliflozin @ mg ( n = @ ) , or dapagliflozin @ mg ( n = @ ) .